{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:47:24Z","timestamp":1784076444559,"version":"3.55.0"},"reference-count":67,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sexual Medicine Reviews"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.sxmr.2020.12.003","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T02:57:23Z","timestamp":1611802643000},"page":"393-405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Testosterone Therapy After Prostate Cancer Treatment: A Review of Literature"],"prefix":"10.1093","volume":"9","author":[{"given":"Caleb","family":"Natale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Carlos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Khera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer A.","family":"Raheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1016\/j.sxmr.2020.12.003_bib1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.urology.2018.07.064","article-title":"Testosterone therapy for high-risk prostate cancer survivors: a systematic review and meta-analysis","volume":"126","author":"Teeling","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2020.12.003_bib2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2013.08.015","article-title":"A\u00a0new era of testosterone and prostate cancer: from physiology to clinical implications","volume":"65","author":"Khera","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2020.12.003_bib3","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.eururo.2015.12.005","article-title":"Testosterone therapy in men with prostate cancer","volume":"69","author":"Kaplan","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2020.12.003_bib4","first-page":"293","article-title":"The effects of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res"},{"key":"10.1016\/j.sxmr.2020.12.003_bib5","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJMp048178","article-title":"Mechanisms of androgen-refractory prostate cancer","volume":"351","author":"Debes","year":"2004","journal-title":"New Engl J Med"},{"key":"10.1016\/j.sxmr.2020.12.003_bib6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.eururo.2009.03.088","article-title":"Testosterone and prostate cancer: revisiting old paradigms","volume":"56","author":"Isbarn","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2020.12.003_bib7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.eururo.2008.09.024","article-title":"\"Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth\"","volume":"55","author":"Morgentaler","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2020.12.003_bib8","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1001\/jama.296.19.2351","article-title":"Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial","volume":"296","author":"Marks","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.sxmr.2020.12.003_bib9","doi-asserted-by":"crossref","first-page":"206","DOI":"10.4103\/1008-682X.148067","article-title":"Testosterone therapy in men with prostate cancer: literature review, clinical experience, and recommendations","volume":"17","author":"Morgentaler","year":"2015","journal-title":"Asian J Androl"},{"key":"10.1016\/j.sxmr.2020.12.003_bib10","first-page":"683","article-title":"Clinically localized prostate cancer: AUA\/ASTRO\/SUO guideline. Part I: risk Stratification, Shared Decision Making, and Care options","volume":"199","author":"Sanda","year":"2018","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2020.12.003_bib11","first-page":"990","article-title":"Clinically localized prostate cancer: AUA\/ASTRO\/SUO guideline. Part II: recommended approaches and details of specific Care options","volume":"199","author":"Sanda","year":"2018","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2020.12.003_bib12","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ucl.2007.08.007","article-title":"The role of testosterone replacement therapy following radical prostatectomy","volume":"34","author":"Khera","year":"2007","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.sxmr.2020.12.003_bib13","first-page":"920","article-title":"Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men","volume":"172","author":"Kaufman","year":"2004","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2020.12.003_bib14","first-page":"533","article-title":"Testosterone replacement therapy after primary treatment for prostate cancer","volume":"173","author":"Agarwal","year":"2005","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2020.12.003_bib15","first-page":"423","article-title":"Evaluation and management of testosterone deficiency: AUA guideline","volume":"200","author":"Mulhall","year":"2018","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2020.12.003_bib16","series-title":"AU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam","author":"Salonia","year":"2020"},{"key":"10.1016\/j.sxmr.2020.12.003_bib17","first-page":"426","article-title":"Outcomes analysis of testosterone supplementation in hypogonadal men following radical prostatectomy","volume":"179","author":"Nabulsi","year":"2008","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2020.12.003_bib18","first-page":"428","article-title":"Analysis of the PSA response after testosterone supplementation in patients who previously received management for their localized prostate cancer","volume":"179","author":"Davila","year":"2008","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2020.12.003_bib19","first-page":"1165","article-title":"Testosterone replacement therapy following radical prostatectomy","volume":"6","author":"Khera","year":"2009","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2020.12.003_bib20","first-page":"e577","article-title":"Testosterone replacement therapy in high risk patients following radical prostatectomy","volume":"183","author":"Sathyamoorthy","year":"2010","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2020.12.003_bib21","first-page":"E576","article-title":"Testosterone treatment after radical prostatectomy for pathologically organ-confined prostate cancer; results from a multi-institutional study","volume":"183","author":"Isbarn","year":"2010","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2020.12.003_bib22","first-page":"E602","article-title":"Long-term follow-up of the safety and efficacy of testosterone replacement therapy following radical prostatectomy","volume":"187","author":"Matsushita","year":"2012","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2020.12.003_bib23","first-page":"639","article-title":"Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy","volume":"190","author":"Pastuszak","year":"2013","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2020.12.003_bib24","first-page":"527","article-title":"Testosterone replacement therapy in patients with prostate cancer after prostatectomy: a 5-year single center experience","volume":"191","author":"Wynia","year":"2014","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2020.12.003_bib25","first-page":"E529","article-title":"Safety of testosterone therapy in men with prostate cancer","volume":"191","author":"Kacker","year":"2014","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2020.12.003_bib26","first-page":"1082","article-title":"Testosterone Therapy in patients with treated and untreated prostate cancer: impact on oncologic outcomes","volume":"196","author":"Ory","year":"2016","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2020.12.003_bib27","first-page":"E206","article-title":"Recurrence rates following testosterone therapy in a large clinical cohort of men with prostate cancer","volume":"199","author":"Morgentaler","year":"2018","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2020.12.003_bib28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/bju.15042","article-title":"Testosterone replacement therapy reduces biochemical recurrence after radical prostatectomy","volume":"126","author":"Ahlering","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2020.12.003_bib29","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2146\/ajhp140128","article-title":"Recurrence of prostate cancer in patients receiving testosterone supplementation for hypogonadism","volume":"72","author":"Gray","year":"2015","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.sxmr.2020.12.003_bib30","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.urolonc.2020.04.008","article-title":"Testosterone replacement therapy (TRT) and prostate cancer: an updated systematic review with a focus on previous or active localized prostate cancer","volume":"38","author":"Lenfant","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.sxmr.2020.12.003_bib31","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.urolonc.2019.06.007","article-title":"Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: a systematic literature review and meta-analysis","volume":"37","author":"Kardoust Parizi","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.sxmr.2020.12.003_bib32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.eururo.2015.11.010","article-title":"Surgery versus radiotherapy for Clinically-localized prostate cancer: a systematic review and meta-analysis","volume":"70","author":"Wallis","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2020.12.003_bib33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ijir.2012.29","article-title":"Testosterone replacement therapy in the setting of prostate cancer treated with radiation","volume":"25","author":"Pastuszak","year":"2013","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.sxmr.2020.12.003_bib34","first-page":"1271","article-title":"Testosterone therapy after radiation therapy for low, intermediate and high risk prostate cancer","volume":"194","author":"Pastuszak","year":"2015","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2020.12.003_bib35","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.soc.2017.01.008","article-title":"Brachytherapy in the management of prostate cancer","volume":"26","author":"Stish","year":"2017","journal-title":"Surg Oncol Clin N Am"},{"key":"10.1016\/j.sxmr.2020.12.003_bib36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/bju.12668","article-title":"Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer","volume":"114","author":"Balbontin","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2020.12.003_bib37","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/cncr.22438","article-title":"Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy","volume":"109","author":"Sarosdy","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.sxmr.2020.12.003_bib38","doi-asserted-by":"crossref","first-page":"132","DOI":"10.5534\/wjmh.180130","article-title":"Testosterone replacement therapy for patients with hypogonadism after high dose-rate brachytherapy for high-risk prostate cancer: a report of six cases and literature review","volume":"38","author":"Kadomoto","year":"2020","journal-title":"World J Mens Health"},{"key":"10.1016\/j.sxmr.2020.12.003_bib39","first-page":"467","article-title":"Management of locally advanced (Nonmetastatic) prostate cancer. Prostate cancer (Second Edition)","author":"Tang","year":"2016","journal-title":"Sci Clin Pract"},{"key":"10.1016\/j.sxmr.2020.12.003_bib40","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1464-410X.2008.07882.x","article-title":"Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations","volume":"103","author":"Morales","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2020.12.003_bib41","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.euf.2019.02.021","article-title":"Late-onset hypogonadism and testosterone therapy \u2013 a summary of guidelines from the American Urological association and the European association of Urology","volume":"5","author":"Fode","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.sxmr.2020.12.003_bib42","first-page":"3474","article-title":"Negative controls of cell proliferation: human prostate cancer cells and androgens","volume":"49","author":"Sonnenschein","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.sxmr.2020.12.003_bib43","doi-asserted-by":"crossref","first-page":"11802","DOI":"10.1073\/pnas.93.21.11802","article-title":"Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride","volume":"93","author":"Umekita","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.sxmr.2020.12.003_bib44","doi-asserted-by":"crossref","first-page":"864","DOI":"10.4103\/1008-682X.129132","article-title":"Physiological normal levels of androgen inhibit proliferation of prostate cancer cells in\u00a0vitro","volume":"16","author":"Song","year":"2014","journal-title":"Asian J Androl"},{"key":"10.1016\/j.sxmr.2020.12.003_bib45","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1186\/s12885-017-3569-x","article-title":"Testosterone inhibits the growth of prostate cancer xenografts in nude mice","volume":"17","author":"Song","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.sxmr.2020.12.003_bib46","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1096\/fj.02-0131fje","article-title":"The human prostate cancer cell line LNCaP bears functional membrane testosterone receptors that increase PSA secretion and modify actin cytoskeleton","volume":"16","author":"Kampa","year":"2002","journal-title":"FASEB J"},{"key":"10.1016\/j.sxmr.2020.12.003_bib47","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1210\/jc.2004-0801","article-title":"Membrane androgen receptor activation induces apoptotic regression of human prostate cancer cells in\u00a0vitro and in\u00a0vivo","volume":"90","author":"Hatzoglou","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2020.12.003_bib48","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1158\/1535-7163.MCT-05-0527","article-title":"Activation of membrane androgen receptors potentiates the antiproliferative effects of paclitaxel on human prostate cancer cells","volume":"5","author":"Kampa","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.sxmr.2020.12.003_bib49","first-page":"824","article-title":"Is low serum free testosterone a marker for high grade prostate cancer?","volume":"163","author":"Hoffman","year":"2000","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2020.12.003_bib50","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.urology.2006.08.1058","article-title":"Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng\/mL or less","volume":"68","author":"Morgentaler","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2020.12.003_bib51","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/00000421-199712000-00015","article-title":"Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer","volume":"20","author":"Ribeiro","year":"1997","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.sxmr.2020.12.003_bib52","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000102906","article-title":"Hormonal predictors of prostate cancer","volume":"79","author":"Sofikerim","year":"2007","journal-title":"Urol Int"},{"key":"10.1016\/j.sxmr.2020.12.003_bib53","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.eururo.2007.03.052","article-title":"Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy","volume":"52","author":"Yamamoto","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2020.12.003_bib54","first-page":"2178","article-title":"Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer","volume":"174","author":"Teloken","year":"2005","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2020.12.003_bib55","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1158\/0008-5472.CAN-04-3992","article-title":"Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice","volume":"65","author":"Chuu","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.sxmr.2020.12.003_bib56","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nm972","article-title":"Molecular determinants of resistance to antiandrogen therapy","volume":"10","author":"Chen","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.sxmr.2020.12.003_bib57","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/pros.22504","article-title":"Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer","volume":"72","author":"Isaacs","year":"2012","journal-title":"Prostate"},{"key":"10.1016\/j.sxmr.2020.12.003_bib58","doi-asserted-by":"crossref","first-page":"269ra2","DOI":"10.1126\/scitranslmed.3010563","article-title":"Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study","volume":"7","author":"Schweizer","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.sxmr.2020.12.003_bib59","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/pros.23209","article-title":"Bipolar androgen therapy for men with androgen ablation Na\u00efve prostate cancer: results from the phase II BATMAN study","volume":"76","author":"Schweizer","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.sxmr.2020.12.003_bib60","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1470-2045(17)30906-3","article-title":"Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study","volume":"19","author":"Teply","year":"2018","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.sxmr.2020.12.003_bib61","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1038\/sj.ijir.3901209","article-title":"Novel nitric oxide signaling mechanisms regulate the erectile response","volume":"16","author":"Burnett","year":"2004","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.sxmr.2020.12.003_bib62","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1095\/biolreprod61.4.1012","article-title":"Androgen-dependent nitric oxide release in rat penis correlates with levels of constitutive nitric oxide synthase isoenzymes","volume":"61","author":"Marin","year":"1999","journal-title":"Biol Reprod"},{"key":"10.1016\/j.sxmr.2020.12.003_bib63","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.eururo.2004.10.021","article-title":"Testosterone regulates PDE5 expression and in\u00a0vivo responsiveness to tadalafil in rat corpus cavernosum","volume":"47","author":"Zhang","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2020.12.003_bib64","first-page":"658","article-title":"Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone","volume":"172","author":"Shabsigh","year":"2004","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2020.12.003_bib65","first-page":"517","article-title":"Dose-response relationship between testosterone and erectile function: evidence for the existence of a critical threshold","volume":"27","author":"Armagan","year":"2006","journal-title":"J\u00a0Androl"},{"key":"10.1016\/j.sxmr.2020.12.003_bib66","first-page":"1056","article-title":"The burden of testosterone deficiency syndrome in adult men: economic and quality-of-life impact","volume":"4","author":"Maggi","year":"2007","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2020.12.003_bib67","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.sxmr.2019.06.003","article-title":"Diagnosis and treatment of testosterone deficiency: updated recommendations from the Lisbon 2018 International Consultation for sexual medicine","volume":"7","author":"Morgentaler","year":"2019","journal-title":"Sex Med Rev"}],"container-title":["Sexual Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2050052120301414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2050052120301414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T19:38:01Z","timestamp":1672774681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2050052120301414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S2050052120301414"],"URL":"https:\/\/doi.org\/10.1016\/j.sxmr.2020.12.003","relation":{},"ISSN":["2050-0521"],"issn-type":[{"value":"2050-0521","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Testosterone Therapy After Prostate Cancer Treatment: A Review of Literature","name":"articletitle","label":"Article Title"},{"value":"Sexual Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sxmr.2020.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}